Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low rate of severe acute respiratory syndrome coronavirus 2 spread among health-care personnel using ordinary personal protection equipment in a medium-incidence setting.
Durante-Mangoni E, Andini R, Bertolino L, Mele F, Bernardo M, Grimaldi M, Cuomo N, Tiberio C, Falco E, Di Spirito A, Raffone M, Russo MG, Atripaldi L, Zampino R. Durante-Mangoni E, et al. Among authors: atripaldi l. Clin Microbiol Infect. 2020 Sep;26(9):1269-1270. doi: 10.1016/j.cmi.2020.04.042. Epub 2020 May 1. Clin Microbiol Infect. 2020. PMID: 32360779 Free PMC article.
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Albisinni R, Vitrone M, Ursi MP, Spiezia S, Salemme A, Florio LL, Boccia F, Iossa D, Zampino R, Atripaldi L, Squillante F, Maturo N, Fraganza F, Severino S, Punzi R, Fiorentino G. Albisinni R, et al. Among authors: atripaldi l. Blood Transfus. 2021 Dec 13. doi: 10.2450/2021.0221-21. Online ahead of print. Blood Transfus. 2021. PMID: 34967728 Free article.
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.
Coppola N, Maraolo AE, Onorato L, Scotto R, Calò F, Atripaldi L, Borrelli A, Corcione A, De Cristofaro MG, Durante-Mangoni E, Filippelli A, Franci G, Galdo M, Guglielmi G, Pagliano P, Perrella A, Piazza O, Picardi M, Punzi R, Trama U, Gentile I. Coppola N, et al. Among authors: atripaldi l. Antibiotics (Basel). 2022 Sep 17;11(9):1263. doi: 10.3390/antibiotics11091263. Antibiotics (Basel). 2022. PMID: 36140042 Free PMC article. Review.
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Albisinni R, Vitrone M, Ursi MP, Spiezia S, Salemme A, Florio LL, Boccia F, Iossa D, Zampino R, Atripaldi L, Squillante F, Maturo N, Fraganza F, Severino S, Punzi R, Fiorentino G. Albisinni R, et al. Among authors: atripaldi l. Blood Transfus. 2022 Nov;20(6):495-504. doi: 10.2450/2021.0211-21. Epub 2021 Dec 13. Blood Transfus. 2022. PMID: 36469432 Free PMC article.
Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A, Sbreglia C, Atripaldi L, Esposito C, D'Antonio A, Perrella O. Perrella A, et al. Among authors: atripaldi l. Scand J Gastroenterol. 2010;45(2):250-5. doi: 10.3109/00365520903428614. Scand J Gastroenterol. 2010. PMID: 19968615
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Montesarchio V, Parrela R, Iommelli C, Bianco A, Manzillo E, Fraganza F, Palumbo C, Rea G, Murino P, De Rosa R, Atripaldi L, D'Abbraccio M, Curvietto M, Mallardo D, Celentano E, Grimaldi AM, Palla M, Trojaniello C, Vitale MG, Million-Weaver SL, Ascierto PA. Montesarchio V, et al. Among authors: atripaldi l. J Immunother Cancer. 2020 Aug;8(2):e001089. doi: 10.1136/jitc-2020-001089. J Immunother Cancer. 2020. PMID: 32784217 Free PMC article.
69 results